Preparation for the relief of disease

Abstract

A composition including (a) a Platelet Activating Factor (PAF) Inhibitor and (b) an antioxidant which interferes with the arachidonic acid cascade and also has antioxidant activity. The composition is useful for the treatment or the relief of inflammatory diseases, thrombosis, cardiac problems, and/or conditions caused by platelet induced blood clotting.

1 . A composition comprising  ginkgo biloba , or an extract or component thereof, and apocynin, wherein the mass ratio of  ginkgo biloba : apocynin is from about 3:10 to 3.4:1.  
   
   
       2 . A composition according to  claim 1 , wherein the apocynin is in isolated form.  
   
   
       3 . A composition according to  claim 1  which comprises apocynin in a natural form.  
   
   
       4 . A composition according to  claim 3 , wherein the apocynin in a natural form is in the form of one or more of picrorrhiza kurroa, apocynum cannabinium, apocynum venatum and apocynum androsaemifolium.  
   
   
       5 . A composition according to  claim 1  which further comprises a surfactant.  
   
   
       6 . A composition according to  claim 1  which further comprises dimethylsulfone.  
   
   
       7 . A composition according to  claim 1  comprising  ginkgo biloba  and apocynin; wherein the ratio by mass of  ginkgo biloba : apocynin is between about 0.5:1 to about 3:1.  
   
   
       8 . A composition according to  claim 7 , wherein the ratio by mass of  ginkgo biloba : apocynin is between about 1:1 and about 3:1.  
   
   
       9 . A pharmaceutical preparation comprising a composition according to  claim 1 .  
   
   
       10 . A pharmaceutical preparation according to  claim 9  for the treatment or the relief of inflammatory diseases, thrombosis, cardiac problems, and/or conditions caused by platelet induced blood clotting.  
   
   
       11 . A pharmaceutical preparation according to  claim 9  for the treatment or the relief of inflammatory respiratory diseases.  
   
   
       12 . A veterinary preparation comprising a composition according to  claim 1 .  
   
   
       13 . A veterinary preparation according to  claim 12  for the treatment or the relief of inflammatory diseases, thrombosis, cardiac problems, and/or conditions caused by platelet induced blood clotting, in a non-human animal.  
   
   
       14 . A pharmaceutical composition comprising  ginkgo biloba , or an extract or component thereof, and apocynin, wherein the mass ratio of  ginkgo biloba : apocynin is from about 3:10 to 60:1.  
   
   
       15 . A pharmaceutical composition according to  claim 14 , wherein the apocynin is in isolated form.  
   
   
       16 . A pharmaceutical composition according to  claim 14  which comprises apocynin in a natural form.  
   
   
       17 . A pharmaceutical composition according to  claim 16 , wherein the apocynin in a natural form is in the form of one or more of picrorrhiza kurroa, apocynum cannabinium, apocynum venatum and apocynum androsaemifolium.  
   
   
       18 . A pharmaceutical composition according to  claim 14  which further comprises a surfactant.  
   
   
       19 . A pharmaceutical composition according to  claim 14  which further comprises dimethylsulfone.  
   
   
       20 . A pharmaceutical composition according to  claim 14 , wherein the ratio by mass of  ginkgo biloba  apocynin is between about 6:1 and about 0.4:1.  
   
   
       21 . An orally active pharmaceutical preparation for the treatment of inflammatory respiratory diseases comprising  ginkgo biloba  and apocynin, wherein the mass ratio of  ginkgo biloba :apocynin is about 3:10 to 60:1.  
   
   
       22 . An orally active pharmaceutical preparation according to  claim 21  for the treatment of asthma.  
   
   
       23 . A method of treating or preventing an inflammatory disease, thrombosis, cardiac problems and/or conditions caused by platelet induced blood clotting, in a human or non-human animal subject, which comprises the step of administering to the subject a composition comprising  ginkgo biloba , or an extract or component thereof, and apocynin, wherein the mass ratio of  ginkgo biloba :apocynin is from about 3:10 to 60:1.  
   
   
       24 . A method according to  claim 23  in which the  ginkgo biloba  is administered to a human at a daily dose of between 1 mg/kg bodyweight and 25 mg/kg body weight, standardized to 24% ginkgo flavone glycosides.  
   
   
       25 . A method according to  claim 23 , in which the apocynin is in an isolated form.  
   
   
       26 . A method according to  claim 25  in which the apocynin is administered to a human at a daily dose of between 60 μg/kg body weight and 20 mg/kg body weight.  
   
   
       27 . A method according to  claim 23  which comprises the step of administering a natural form of apocynin.  
   
   
       28 . A kit containing a preparation for treating or preventing an inflammatory disease, thrombosis, cardiac problems and/or conditions caused by platelet induced blood clotting in a human or non-human animal subject, comprising at least one dose of  ginkgo biloba , or an extract or component thereof, and at least one dose of apocynin, wherein the mass ratio of  ginkgo biloba :apocynin in said doses of  ginkgo biloba , or an extract or component thereof, and apocynin is 3:10 to 60:1.  
   
   
       29 . A method of dose sparing a therapeutic agent comprising the step of administering to a patient a preparation comprising  ginkgo biloba , or an extract of component thereof, and apocynin, wherein the mass ratio of  ginkgo biloba :apocynin is from about 3:10 to 60:1.  
   
   
       30 . A composition according to  claim 7 , wherein the mass ratio of  ginkgo biloba :apocynin is from about 2.1:1 to about 2.7:1.  
   
   
       31 . A method of treating or preventing an inflammatory respiratory disease in a human or a non-human animal subject comprising the step of administering to the subject  ginkgo biloba , or an extract or component thereof, apocynin, wherein the mass ratio of  ginkgo biloba :apocynin is from about 3:10 to about 60:1.  
   
   
       32 . A method according to  claim 31 , in which the  ginkgo biloba  is administered to a human at a daily dose of between 1 mg/kg body weight and 25 mg/kg body weight, standardized to 24% ginkgo flavone glycosides.  
   
   
       33 . A method according to  claim 31 , in which the apocynin is in an isolated form.  
   
   
       34 . A method according to  claim 31 , which comprises administering a natural form of the apocynin.  
   
   
       35 . A pharmaceutical composition comprising apocynin, picrorrhiza kurroa and  ginkgo biloba , or an extract or component thereof, wherein the mass ratio of  ginkgo biloba : apocynin is from about 3:10 to 60:1.  
   
   
       36 . A composition according to  claim 1 , consisting essentially of  ginkgo biloba , or an extract of component thereof, and apocynin.  
   
   
       37 . A composition according to  claim 1 , consisting of  ginkgo biloba , or an extract or component thereof, apocynin and, optionally, at least one of picrorrhiza kurroa, a surfactant and dimethylsulfone.  
   
   
       38 . A pharmaceutical composition according to  claim 14 , consisting essentially of  ginkgo biloba , or an extract or component thereof, and apocynin.  
   
   
       39 . A pharmaceutical composition according to  claim 14 , consisting of  ginkgo biloba , or an extract or component thereof, apocynin and, optionally, at least one of picrorrhiza kurroa, a surfactant and dimethylsulfone.  
   
   
       40 . An orally active pharmaceutical preparation according to  claim 21 , consisting essentially of  ginkgo biloba , or an extract of component thereof, and apocynin.  
   
   
       41 . An orally active pharmaceutical preparation according to  claim 21 , consisting of  ginkgo biloba , or an extract or component thereof, apocynin and, optionally, at least one of picrorrhiza kurroa, a surfactant and dimethylsulfone.  
   
   
       42 . A method according to  claim 23 , wherein the composition consists essentially of  ginkgo biloba , or an extract or component thereof, and apocynin.  
   
   
       43 . A method according to  claim 23 , wherein the composition consists of  ginkgo biloba , or an extract or component thereof, apocynin and, optionally, at least one of picrorrhiza kurroa, a surfactant and dimethylsulfone.  
   
   
       44 . A kit according to  claim 28 , wherein the preparation consists essentially of  ginkgo biloba , or an extract or component thereof, and apocynin.  
   
   
       45 . A kit according to  claim 28 , wherein the preparation consists of  ginkgo biloba , or an extract or component thereof, apocynin and, optionally, at least one of picrorrhiza kurroa, a surfactant and dimethylsulfone.  
   
   
       46 . The method according to  claim 29 , wherein the preparation consists essentially of  ginkgo biloba , or an extract or component thereof, and apocynin.  
   
   
       47 . The method according to  claim 29 , wherein the preparation consists of  ginkgo biloba , or an extract or component thereof, apocynin and, optionally, at least one of picrorrhiza kurroa, a surfactant and dimethylsulfone.